Comparison of the efficacy of amisulpride and risperidone in the treatment of patients with first -episode schizophrenia
10.3760/cma.j.issn.1008-6706.2017.05.027
- VernacularTitle:氨磺必利与利培酮治疗首发精神分裂症临床效果比较
- Author:
Tongbao ZHAN
- Keywords:
] Schizophrenia;
Amisulpride;
Risperidone
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(5):743-746
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare and analyze the efficacy and safety of amisulpride and risperidone in the treatment of patients with first -episode schizophrenia(FES).Methods 80 patients with FES were randomly divided into the observation group (n =40,orally given amisulpride)and the control group (n =40,orally given risperidone) according to random number table.The total effective rate,positive and negative symptoms scale (PANSS),adverse reaction rate of two groups were compared.Results 1 week after treatment,the negative symptoms score of the observation group was significantly lower than that of the control group [(20.89 ±3.07 )points vs.(18.15 ± 3.64)points,t =3.639,P =0.001].8 weeks after treatment,the PANSS scores and factor score of the two groups had no significant differences(all P >0.05).The total effective rate and adverse reaction rate of the observation group were 90.00%,17.50% respectively,which of the control group were 82.50%,27.50% respectively,there were no statistically significant differences (χ2 =0.949,P =0.330;χ2 =1.147,P =0.284).Conclusion Amisulpride and risperidone has similar efficacy and safety in the treatment of patients with FES,but amisulpride has better early effect in improving negative symptoms.
